Status and phase
Conditions
Treatments
About
This multicenter, open-label extension study of Protocol 2993-112 is designed to assess long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate long-term safety and tolerability in subjects treated with metformin who receive subcutaneously injected AC2993 (10 mcg) administered twice daily. Subjects completing Protocol 2993-112 are eligible to enroll.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
All of the following criteria are to be fulfilled for inclusion of an individual in the study unless the sponsor grants an exception:
Individuals meeting any of the following criteria are to be excluded from the study unless the sponsor grants an exception:
Primary purpose
Allocation
Interventional model
Masking
225 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal